Registry Study of Pharmacotherapy and Clinical Outcomes in Elderly Patients With Coronary Heart Disease (PHARM-ageing)
1 other identifier
observational
15,000
0 countries
N/A
Brief Summary
A registry study on drug therapy and clinical outcomes in elderly patients with coronary heart disease
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2022
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 13, 2022
CompletedStudy Start
First participant enrolled
February 1, 2022
CompletedFirst Posted
Study publicly available on registry
February 18, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2025
CompletedFebruary 18, 2022
February 1, 2022
2.8 years
January 13, 2022
February 9, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
main adverse cardiovascular and cerebrovascular events (MACCE)
MACCE will be defined as all-cause death, non-fatal stroke, non-fatal myocardial infarction (MI), and ischemic-driven revascularization
up to 3 years
Secondary Outcomes (1)
Adverse drug reaction
up to 3 years
Eligibility Criteria
Elderly patients (≥65 years) with coronary heart disease who discharged at Beijing Anzhen Hospital from January 1, 2019.Those who fill the inclusion criteria at screening will be invited for the registry study.
You may qualify if:
- Informed consent has been signed
- Patients diagnosed in our hospital with coronary heart disease
- Age ≥65 years
You may not qualify if:
- Severe lack of important information such as history of previous medication, history of previous disease, history of surgery.
- Mental disorders, or inability to communicate effectively with researchers, or failure to comply with research protocols.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Target Duration
- 3 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director of pharmacy department of Beijing Anzhen Hospital
Study Record Dates
First Submitted
January 13, 2022
First Posted
February 18, 2022
Study Start
February 1, 2022
Primary Completion
December 1, 2024
Study Completion
December 1, 2025
Last Updated
February 18, 2022
Record last verified: 2022-02